IFN-γ also upregulated Qa-1 and HLA-E on murine and human tumour cells, respectively, and blocking NKG2A converted cancer vaccines into effective therapies in four different solid tumour models (TC-1 lung epithelial tumour, B16F10 melanoma, RMA T cell lymphoma, and MC38 colon carcinoma) [67]. This evidence concerns the gene IFNG and cancer.